Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa

Article Outline

• Abstract
• Materials and Methods
  • Patients and Study Design
  • Laboratory Testing
  • Statistical Analysis
• Results
  • Predictors of Sustained Response
  • Performance of the Model
  • Application of the Model in Clinical Practice
• Discussion
• Acknowledgments
• Podcast
• References
• Copyright

Background & Aims

Therapy with pegylated interferon (PEG-IFN)–alfa results in sustained response in a minority of patients with chronic hepatitis B virus (HBV) infection and has considerable side effects. We analyzed data from the 2 largest global trials of hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B to determine which are most likely to respond to PEG-IFN–alfa therapy.

Methods

The study included 542 patients treated with PEG-IFN–alfa-2a (180 μg/wk, 48 wk) and 266 patients treated with PEG-IFN–alfa-2b (100 μg/wk, 52 wk). Eighty-seven patients were excluded, leaving 721 patients for analysis. A sustained response was defined as HBeAg loss and HBV-DNA level less than 2.0 × 10³ IU/mL 6 months after treatment. Logistic regression analysis was used to identify predictors of sustained response and a multivariable model was constructed.

Results

HBV genotype, high levels of alanine aminotransferase (ALT; ≥2 × upper limit of normal), low levels of HBV DNA (<2.0 × 10⁸ IU/mL), female sex, older age, and absence of previous IFN therapy predicted a sustained response. Genotype A patients with high ALT and/or low HBV-DNA levels had a high predicted probability (>30%) of a sustained response. The strongest predictors of response were a high level of ALT in genotype B patients and a low level of HBV DNA in genotype C patients. Genotype D patients had a low chance of sustained response, irrespective of ALT or HBV-DNA levels.

Conclusions

The best candidates for a sustained response to PEG-IFN–alfa are genotype A patients with high levels of ALT or low levels of HBV DNA, and genotypes B and C patients who have both high levels of ALT and low HBV DNA. Genotype D patients have a low chance of sustained response.

Abbreviations used in this paper: ALT, alanine aminotransferase, AUC, area under the receiver-operating characteristic curve, CI, confidence interval, HBeAg, hepatitis B e antigen, HBV, hepatitis B virus, HCC, hepatocellular carcinoma, OR, odds ratio, PEG-IFN, peginterferon, ULN, upper limit of normal

Hepatitis B is a major global health problem. The World Health Organization reported that there are more than 400 million carriers in the world, approximately 75% of whom reside in Asia and the Western Pacific.¹ In this part of the world, hepatitis B virus (HBV) infection usually is acquired perinatally or in early childhood. Most patients from these areas typically have hepatitis B e antigen (HBeAg)-positive chronic hepatitis B with high HBV-DNA levels, and they develop moderate to severe hepatic inflammation with increased alanine aminotransferase (ALT) levels after 10–30 years of infection.² In contrast, patients infected in late childhood, adolescence, or adulthood present with increased aminotransferase levels after a shorter duration of infection. Although spontaneous HBeAg seroconversion occurs in the majority of HBeAg-positive patients, the duration of hepatic inflammation can be prolonged and severe, and may result in cirrhosis. Therefore, antiviral treatment is indicated in patients who remain HBeAg positive with high HBV-DNA levels after a 3- to 6-month period of increased ALT levels.³

Successful treatment of chronic HBV infection with loss of HBeAg, decline in serum HBV-DNA level, and normalization of ALT level is associated with favorable long-term outcome, independent of the antiviral drug used.⁴, ⁵ In HBeAg-positive patients, sustained clearance of HBeAg from serum is associated with a higher likelihood of losing hepatitis B surface antigen (HBsAg), reduced incidence of cirrhosis and hepatocellular carcinoma (HCC), and improved survival.⁵, ⁶, ⁷, ⁸ Of currently available drugs for the treatment of chronic hepatitis B, pegylated interferon (PEG-IFN) still results in the highest rate of off-treatment sustained response after a 1-year course of therapy.⁹, ¹⁰, ¹¹, ¹² Furthermore, responders to IFN-based therapy have a considerable chance of losing HBsAg, which has been observed in 12%–65% of patients within 5 years after HBeAg loss.⁷, ⁸, ¹³, ¹⁴, ¹⁵, ¹⁶, ¹⁷, ¹⁸ Treatment with PEG-IFN, however, often is complicated by the occurrence of side effects such as flu-like symptoms, cytopenia, and depression.¹⁹ Nucleos(t)ide analogues such as lamivudine, adefovir, entecavir, and tenofovir on the other hand are well tolerated, but because of the modest seroconversion rate and the high risk of posttreatment relapse, prolonged therapy usually is required.²⁰ Nowadays, maintenance of virologic response over prolonged periods is feasible,²¹ but still may pose a considerable risk for resistance in the long term.²², ²³, ²⁴

Because treatment with both PEG-IFN and nucleos(t)ide analogues has proven effective, but also have their advantages and limitations, the question arises of what treatment regimen should be used as first-line therapy in which patients. Both the chance of achieving response and specific patient characteristics play a role in the decision on what type of antiviral therapy should be started. Recently performed studies with 1 year of PEG-IFN in HBeAg-positive patients identified high baseline ALT levels, low baseline HBV-DNA levels, absence of previous IFN therapy, low baseline HBeAg levels, and HBV genotype A or B as predictors of response.¹⁰, ²⁵, ²⁶ Current guidelines do not provide specific recommendations as to which patients should be treated with peginterferon²⁷; the earlier-mentioned studies were considered to provide insufficient evidence for such recommendations. The aim of this study therefore was to develop a solid model for the prediction of sustained response to PEG-IFN in individual HBeAg-positive patients, which would allow physicians throughout the world to choose the optimal candidates for treatment with this drug.

Back to Article Outline

Materials and Methods 

Patients and Study Design 

Individual data of 542 patients treated with PEG-IFN–alfa-2a 180 μg/wk for 48 weeks (271 patients with added lamivudine 100 mg/day) and 266 patients treated with PEG-IFN–alfa-2b 100 μg/wk for 52 weeks (130 patients with added lamivudine 100 mg/day) were analyzed.¹⁰, ¹¹ Posttreatment follow-up evaluation lasted 6 months. Addition of lamivudine did not influence response rates at the end of the follow-up period (6 months posttreatment) in any way. For the current study, sustained response was defined as clearance of HBeAg from serum and HBV DNA less than 10,000 copies/mL (2000 IU/mL) at 6 months after treatment.

The inclusion and exclusion criteria were reported in detail previously and were similar for the 2 studies.¹⁰, ¹¹ In short, patients were eligible if they had been HBsAg positive for at least 6 months, were HBeAg positive, had increased serum ALT levels between 1 and 10 times the upper limit of normal (ULN), had serum HBV-DNA levels greater than 1.0 × 10⁵ copies/mL (2.0 × 10⁴ IU/mL), and had findings on a liver biopsy within the preceding 12 months that were consistent with the presence of chronic hepatitis B. Exclusion criteria included decompensated liver disease, antiviral therapy within 6 months before randomization, viral co-infections (hepatitis C virus, hepatitis delta virus, or human immunodeficiency virus), or pre-existent neutropenia or thrombocytopenia.

Laboratory Testing 

During therapy and posttreatment follow-up evaluation, all patients were monitored monthly by routine physical examination, as well as biochemical and hematologic assessments. ALT level was assessed locally and therefore expressed as times ULN. HBV DNA was assessed monthly using an in-house–developed Taqman (Applied Biosystems Inc, Foster City, CA) polymerase chain reaction assay based on the Eurohep standard (lower limit of detection, 373 copies/mL) or the Cobas Amplicor HBV Monitor Test (Roche Diagnostics, Basel, Switzerland).²⁸ We compared the 2 HBV-DNA quantification assays and found an excellent correlation between the 2 assays (r = 0.930, P < .001). Plotting the difference against the average of the assays showed no significant correlation (Bland–Altman test; r = 0.12, P = .49), strengthening the conclusion that both assays are comparable in the dynamic range.⁶ HBeAg, anti-HBe, HBsAg, and anti-HBs were measured with the use of the AxSYM test (Abbott, Abbott Park, IL). HBV genotype analysis was performed by INNO-LiPA Assay (Innogenetics, Gent, Belgium).

Statistical Analysis 

Statistical analysis was performed using the SPSS 15.0 program (SPSS, Inc, Chicago, IL) and the R 2.3.1 Project for Statistical Computing (Harrell's Design, HMisc and Foreign libraries).²⁹ A P value less than .05 was considered statistically significant (all 2-tailed). We performed univariate logistic regression analysis to identify predictors of sustained response among the variables of age, sex, HBV genotype (A–D), serum HBV DNA (log₁₀ copies/mL), ALT (ln ALT × ULN), treatment allocation (PEG-IFN monotherapy or combination therapy of PEG-IFN and lamivudine), and previous treatment with IFN or lamivudine. We used multivariable logistic regression analysis with backward stepwise selection, using a P value greater than .05 for removal of variables, to construct a multivariable linear model that provides a natural logarithm transformed prediction of sustained response. We used restricted cubic spline functions to assess the linearity of the effect of continuous variables. Interactions between variables were explored. Odds ratios (ORs) were calculated with 95% confidence intervals (95% CI). Because there were interactions between HBV genotype and other factors, ORs for HBV genotype were calculated for 33-year-old (mean age), IFN-naive men with ALT and HBV-DNA levels fixed at 2 × ULN and 1.0 × 10⁹ copies/mL (2.0 × 10⁸ IU/mL), respectively.

Discrimination, which is the ability to distinguish patients who will achieve sustained response from those who will not, was quantified by the area under the receiver-operating characteristic curve (AUC). An AUC of 0.5 indicates no discriminative ability at all, whereas an AUC of 1.0 indicates perfect discrimination. Internal validity was assessed with bootstrap sampling.³⁰, ³¹ Two hundred bootstrap samples were drawn with replacement and with the same size as the original sample. The final prediction model was constructed by applying the penalized maximum likelihood estimation acquired from the bootstrap samples.³² Nomograms for IFN-naive patients were constructed based on the logistic regression formulas. A nomogram allows for the approximate graphic computation of sustained response with points allocated to each variable based on the logistic regression formula. To develop a simple rule for each of the genotypes independent of sex and age, the predicted probability of sustained response in different patient subgroups was calculated with the logistic regression formulas. Because sex and age also predicted sustained response, but were not included in the flowchart, age was fixed at the respective mean value of each subgroup and the mean predicted probability of sustained response for males and females was calculated. For serum ALT, a low level (<2 × ULN) was considered to be between 1 × ULN and 2 × ULN, and a high level (≥2 × ULN) was considered to be between 2 × ULN and 10 × ULN. For serum HBV DNA, a low level (<1.0 × 10⁹ copies/mL [<2.0 × 10⁸ IU/mL]) was considered to be between 1.0 × 10⁷ copies/mL (2.0 × 10⁶ IU/mL) and 1.0 × 10⁹ copies/mL (2.0 × 10⁸ IU/mL), and a high level (≥1.0 × 10⁹ copies/mL [≥2.0 × 10⁸ IU/mL]) was considered to be between 1.0 × 10⁹ copies/mL (2.0 × 10⁸ IU/mL) and 1.0 × 10¹¹ copies/mL (2.0 × 10¹⁰ IU/mL). These cut-off levels were chosen because the majority of patients had ALT (95%) and HBV-DNA (80%) levels between these values. In addition, these cut-off levels generally are used in clinical practice and are recommended by international guidelines for the treatment of chronic hepatitis B.³, ²⁷, ³³, ³⁴

Back to Article Outline

Results 

Of 808 patients eligible for participation in this study, 87 were excluded because of missing values (n = 76) or infection with HBV genotype other than A–D (n = 11), leaving 721 patients for analysis. HBeAg loss, HBeAg seroconversion, and HBV-DNA level less than 10,000 copies/mL (<2.0 × 10³ IU/mL) were observed in 254 (35.2%), 232 (32.2%), and 174 (24.1%) of 721 patients, respectively. Sustained response, defined as HBeAg loss and HBV-DNA level less than 10,000 copies/mL (<2.0 × 10³ IU/mL) at 6 months posttreatment, was observed in 158 of 721 patients (21.9%). Sustained response was observed in 22.4% of patients treated with PEG-IFN alone and in 21.4% of those treated with PEG-IFN and lamivudine combination therapy (P = .73). Sustained response was observed in 37% of patients with genotype A, 25% with genotype B, 20% with genotype C, and 8% with genotype D.

There were no differences in baseline characteristics between patients enrolled and those excluded from participation in this study, except for a lower rate of previous IFN therapy among the participants than the excluded patients (14% vs 24%; P = .01). Baseline characteristics of patients with and without sustained response are given in Table 1. Patients with sustained response were older, more often were female, had higher baseline ALT and lower HBV-DNA levels, and were more likely to have genotype A but less likely to have genotype D infection compared with those without sustained response. The proportion of patients who previously were treated with IFN or lamivudine therapy did not differ between patients with sustained response and those without.

Table 1. Baseline Characteristics and Univariate Logistic Regression Analysis

Characteristic	Sustained responsea (n=158)	No sustained response (n=563)	OR	95% CI		P
				Lower	Upper
Age, y	34.8±11.4	32.4±10.6	1.02	1.00	1.04	.01
Female sex	47(29.7%)	120(21.3%)	1.56	1.05	2.32	.03
Serum ALT level, × ULN	4.3±3.0	3.9±3.5	1.31	1.02	1.69	.03
HBV-DNA level, log10copies/mL	9.4±1.7	9.8±1.8	0.85	0.77	0.95	.003
HBV genotype						<.001
A	42(26.6%)	73(13.0%)	1.00
B	41(25.9%)	125(22.2%)	0.57	0.34	0.96
C	67(42.4%)	266(47.2%)	0.44	0.28	0.70
D	8(5.1%)	99(17.6%)	0.14	0.06	0.32
Previous IFN therapy	22(13.9%)	79(14.0%)	0.99	0.60	1.65	.97
Previous lamivudine therapy	16(10.1%)	64(11.4%)	0.88	0.49	1.57	.66

NOTE. For age, ALT, and HBV DNA the mean ± SD is given.

Predictors of Sustained Response 

Factors associated with an increased likelihood of sustained response included HBV genotype A infection, high baseline ALT level, low baseline HBV-DNA level, female sex, and older age (Table 1). There was no association between sustained response and previous treatment with IFN or lamivudine on univariate analysis. By using multivariate analysis, high baseline ALT was found to be an independent predictor of sustained response (OR, 1.57 per 1 log₁₀ × ULN increase; 95% CI, 1.19–2.09; P = .002). In addition, HBV genotype was associated with sustained response, with higher rates of sustained response in patients with genotype A (OR, 1; reference) than B (OR_B vs OR_A, 0.46; 95% CI, 0.21–0.99; P = .05), C (OR_C vs OR_A, 0.30; 95% CI, 0.16–0.59; P < .001), or D (OR_D vs OR_A, 0.08; 95% CI, 0.02–0.31; P < .001). The influence of sex, age, HBV DNA, and previous IFN therapy was significantly different across HBV genotypes (P < .02 for the interaction between HBV genotype and each of these factors). These variables therefore also were included in the model. We here describe the most important predictive factors. Genotype C– and D–infected females had a significantly higher chance of sustained response compared with males (OR, 2.78; 95% CI, 0.51–5.11; and OR, 7.69; 95% CI, 1.48–39.90; P < .02). Older age was associated with a significantly higher chance of sustained response in genotype A–infected patients (OR, 1.04 per year increase in age; 95% CI, 1.01–1.08; P = .01). High baseline HBV-DNA level was associated with a lower likelihood of sustained response in patients with genotypes A (OR, 0.57; 95% CI, 0.40–0.82; P = .003) and C (OR, 0.77; 95% CI, 0.65–0.91; P = .002). Previous IFN therapy resulted in a significantly lower chance of sustained response in patients with genotype A or D (OR, 0.21; 95% CI, 0.07–0.58; P = .003). We found no differences in the predictors of response for the 2 treatment groups.

Performance of the Model 

The distribution of the predicted probabilities of sustained response in genotypes A–D is shown in Figure 1. The agreement between the predicted probabilities and the observed frequency of sustained response was good (P = .27 by the Hosmer–Lemeshow goodness-of-fit test). A multivariable model including the variables of age, sex, ALT level, HBV-DNA level, HBV genotype, and previous IFN therapy had adequate discriminative ability as shown by an AUC of 0.72 (95% CI, 0.67–0.77). The AUC was 0.75 (95% CI, 0.65–0.85), 0.65 (95% CI, 0.55–0.75), 0.68 (95% CI, 0.61–0.75), and 0.78 (95% CI, 0.65–0.92) for genotypes A–D, respectively. After bootstrap validation, the AUC was 0.69 (95% CI, 0.60–0.77). Because the influence of the predictors was significantly different across genotypes, a validated formula for the prediction of sustained response was generated for each HBV genotype separately. The PEG-IFN HBV Treatment Index is based on these formulas (Figure 2). An automated calculator can be found at www.liver-gi.nl/peg-ifn.

• 
  • View Large Image
  • Download to PowerPoint

• Figure 1. 

  Distribution of predicted probabilities of sustained response in patients with HBV genotypes A–D. Boxplots show the distribution of the predicted probabilities of sustained response, defined as HBeAg loss and HBV DNA less than 10,000 copies/mL at 6 months posttreatment, in patients with genotype A (n = 115), B (n = 166), C (n = 333), or D (n = 107).

• 
  • View Large Image
  • Download to PowerPoint

• Figure 2. 

  PEG-IFN HBV treatment index. These nomograms can be used to obtain a patient-tailored predicted probability of sustained response in IFN-naive patients with genotypes A–D based on ALT level, HBV-DNA level, sex, and age. The probability of sustained response is calculated by drawing a vertical line to the top points axis for each of the 4 variables ALT, HBV DNA, age, and sex. The points for each variable then are summed and located on the total points axis, and a vertical line is projected from the total points axis to the bottom scale to get the predicted probability of sustained response. For example, a genotype C–infected woman (62 points), age 25 (67 points), with serum ALT level of 2.7 × ULN (25 points), and serum HBV-DNA level of 9.2 log₁₀ copies/mL (40 points) has a total score of 194 points, which converts to a probability of sustained response of 37%.

Application of the Model in Clinical Practice 

To allow for application of the model in clinical practice, a nomogram for IFN-naive patients was generated from the validated formula for each of the HBV genotypes separately (Figure 2). These nomograms can be used for calculating the probability of sustained response in individual HBeAg-positive patients based on their sex, age, and ALT and HBV-DNA levels. Average response rates based on the presence of low (<2 × ULN) or high ALT levels (≥2 × ULN), and low (<9 log₁₀ copies/mL [<2.0 × 10⁸ IU/mL]) or high HBV-DNA levels (≥9 log₁₀ copies/mL [≥2.0 × 10⁸ IU/mL]) are shown in Figure 3.

• 
  • View Large Image
  • Download to PowerPoint

• Figure 3. 

  Flowcharts to easily obtain average predicted probabilities of sustained response in patients infected with HBV genotypes A–D. These flowcharts show the average predicted probability of sustained response depending on HBV genotype, ALT level (> or <2 × ULN), and HBV-DNA level (> or <9 log₁₀ copies/mL). For a precise estimate of the probability of sustained response in an individual patient, the nomograms in Figure 2 can be used.

Back to Article Outline

Discussion 

We combined the data of the 2 largest studies investigating PEG-IFN in HBeAg-positive chronic hepatitis B to develop a model for the prediction of response to PEG-IFN in all HBV genotypes. Although the model is based on the data of patients enrolled in randomized clinical trials with predefined inclusion and exclusion criteria, generalizability of our results probably is good because of the large sample size and wide geographic distribution of the patients. We provided nomograms that can be used to calculate the predicted probability of response in individual patients. A rapid estimate can be obtained from the provided flowcharts.

We recommend starting PEG-IFN therapy in patients with the highest chance of achieving sustained response (Table 2). We arbitrarily chose those with a predicted probability of sustained response of at least 30% to be good candidates for PEG-IFN therapy. About 25% of patients included in this study had a predicted probability of sustained response above this level. This includes all HBV genotype A–infected patients, except for those with low ALT and high HBV-DNA levels. In addition, genotypes B- and C–infected patients with high ALT and low HBV-DNA levels have a high likelihood of response to PEG-IFN. All remaining patients are moderate candidates for PEG-IFN except for those with genotype D, who have a rather low chance of achieving sustained response and are in our view generally not candidates for treatment with PEG-IFN. It should be noted that Table 2 provides recommendations for patient groups, not individual patients. In selected patients, the given response rate in Table 2 thus may differ slightly from the more accurate predicted probability of response obtained from the nomograms.

Table 2. Recommendations for the Use of PEG-IFN as Initial Antiviral Therapy

NOTE. The recommendation to consider PEG-IFN therapy is based on an average predicted probability of SVR of at least 30%. Predicted SVR rates may be higher or lower in selected subgroups of patients. In patients with a predicted probability of SVR less than 30%, cofactors such as age and comorbidity can be taken into account when deciding whether or not to start PEG-IFN therapy.

With the licensing of PEG-IFN and an additional 5 nucleos(t)ide analogues for the treatment of chronic hepatitis B in past years, choice of antiviral therapy has become more important and more complex at the same time. Because both treatment with IFN-based therapy and nucleos(t)ide analogue therapy have proven effective and can improve long-term outcome, the pros and cons of these drugs as well as patient-specific characteristics should be taken into consideration. All of the major practice guidelines have advocated IFN-based therapy as potential first-line therapy for both HBeAg-positive and HBeAg-negative patients,³, ²⁷, ³³, ³⁴ particularly because sustained response and HBsAg loss seem to occur more often with IFN and PEG-IFN than with the direct antiviral agents.²⁰ To reduce the risk of relapse, nucleos(t)ide analogue therapy can be extended for several months after HBeAg seroconversion because this reduces relapse rates.³⁵, ³⁶ HBeAg seroconversion was sustained in 86% of patients treated with telbivudine or lamivudine who discontinued therapy after at least 6 months of maintenance therapy.³⁷, ³⁸ Whether these responses also can be sustained in the long term, however, still is unknown.

However, the use of PEG-IFN currently accounts for no more than 10% of all prescriptions for the treatment of chronic hepatitis B.³⁹ The relatively low use of PEG-IFN may be explained by its significant side effects and need for administration by injection. Furthermore, recommendations on the use of PEG-IFN in specific subsets of patients who are most likely to have a sustained response and HBsAg seroconversion were lacking. When we are able to identify patients with a high likelihood of response to PEG-IFN, the proportion of patients achieving sustained response after treatment with this drug probably can be increased.

Most studies investigating IFN-based therapy in HBeAg-positive chronic hepatitis B found that high baseline ALT level, low baseline HBV-DNA level, and HBV genotype A or B were associated with response.¹⁰, ²⁵, ²⁶, ⁴⁰ In addition to these factors, we identified sex and age as predictors of response to PEG-IFN. It should be mentioned that in both studies more men than women were included. We found that the influence of sex, age, HBV DNA, and previous IFN therapy was significantly different across HBV genotypes. HBV genotype thus has great influence on the outcome of PEG-IFN therapy. Therefore, contrary to a statement on this topic in the newest guidelines from the European Association for the Study of the Liver,²⁷ we believe that determination of HBV genotype is essential in all patients in whom sustained off-treatment response is pursued. Other potential approaches to tailor PEG-IFN therapy in chronic hepatitis B include quantification of serum HBeAg and HBsAg.⁴¹ These approaches still are being validated and are not routinely available to most physicians. Because of limited availability in clinical practice, we also chose not to include liver histology.

Previously we presented a model based on 266 HBeAg-positive patients participating in a single randomized trial.⁴² However, a vast majority of these patients were infected with HBV genotype A or D; only a small proportion of patients harbored HBV genotype B or C. To gain a good prediction model for all HBeAg-positive patients, we now combined the data of the 2 largest randomized trials investigating PEG-IFN in HBeAg-positive chronic hepatitis B. We showed that a model based on readily available baseline factors can provide an adequate prediction of sustained response. Ideally, a large confirmatory group would have been used for external validation. Unfortunately, such a group is not available. Clinical trials that currently still are ongoing may allow for further validation of the model in the near future.

Because substantial viral replication may persist despite HBeAg loss in some patients, a combined end point of HBeAg clearance from serum and low HBV-DNA level is crucial in HBeAg-positive chronic hepatitis B. Particularly, patients with HBV genotype non-A infection can develop mutations in the precore or core promoter region and still may be at risk for progressive liver disease despite HBeAg loss.⁶, ⁴³ Both clearance of HBeAg and suppression of HBV replication are key events in the natural course and during antiviral therapy in HBeAg-positive chronic hepatitis B. HBeAg loss after IFN-based therapy was associated with reduced progression to cirrhosis and HCC, and improved survival.⁵, ⁴⁴ In addition, large population studies have established a clear link between HBV viremia and the risk for HBV-related complications.⁴⁵, ⁴⁶ Serum HBV DNA was the strongest predictor of progression to cirrhosis and HCC, with a significantly higher risk for patients with an HBV-DNA level greater than 10,000 copies/mL (2000 IU/mL) as compared with those with a serum HBV-DNA level less than 300 copies/mL (relative risk, 2.5; 95% CI, 1.6–3.8; and relative risk, 2.3; 95% CI, 1.1–4.9 for developing cirrhosis and HCC, respectively). Although the proportion of patients with undetectable HBV DNA was relatively low shortly after PEG-IFN therapy,¹⁰ it further increased with prolonged duration of follow-up evaluation.⁶ Because the presence of anti-HBe at 6 months posttreatment was not associated with long-term sustainability of response to PEG-IFN,⁶ the combined end point of HBeAg loss and low HBV DNA seems optimal.

The parties involved in this study agreed not to perform a direct comparison between the 2 formulations of PEG-IFN. However, the previously reported results of 2 studies included in this retrospective analysis were very similar.¹⁰, ¹¹ Unfortunately, we cannot provide recommendations for HBeAg-negative patients because we only had data of HBeAg-positive patients treated with PEG-IFN. Because of the low sustained response rate in HBeAg-negative patients,⁴⁷ PEG-IFN is given relatively less often to HBeAg-negative as compared with HBeAg-positive patients. Prediction of response to PEG-IFN therefore seems of greater importance in HBeAg-positive than in HBeAg-negative chronic hepatitis B.

In conclusion, we provide a practical tool to calculate the probability of sustained response to PEG-IFN in individual HBeAg-positive patients, which easily can be used in clinical practice and thus can allow for the selection of the optimal candidates for PEG-IFN therapy. Unfortunately, we were not able to perform external validation because such a database is not available. Clearly, this should be performed when an appropriate patient group is available. We recommend consideration of PEG-IFN therapy in all genotype A patients with either high ALT or low HBV-DNA levels, and in genotypes B– and C–infected patients with both high ALT and low HBV-DNA levels. HBeAg-positive genotype D–infected patients are generally not good candidates for treatment with PEG-IFN.

Back to Article Outline

Acknowledgments 

The authors thank Dr Richard Batrla (Roche, Basel, Switzerland), Dr Philip McCloud (Roche, Dee Why, Australia), Peter Button (Roche, Dee Why, Australia), and Schering-Plough International (Kenilworth, NJ) for supporting this study. In addition, the authors thank all investigators of the Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group and the HBV99-01 Study Group.

E.H.C.J.B. and B.E.H. contributed equally to this study.

Back to Article Outline

Podcast 

Back to Article Outline

References 

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107
   • View In Article
   • MEDLINE
   • CrossRef
2. Lok AS, Lai CL, Wu PC, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology. 1987;92:1839–1843
   • View In Article
   • Abstract
   • Full-Text PDF (606 KB)
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–539
   • View In Article
   • MEDLINE
   • CrossRef
4. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531
   • View In Article
   • CrossRef
5. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology. 2004;39:804–810
   • View In Article
   • MEDLINE
   • CrossRef
6. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135:459–467
   • View In Article
   • Abstract
   • Full Text
   • Full-Text PDF (471 KB)
   • CrossRef
7. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology. 1997;113:1660–1667
   • View In Article
   • Abstract
   • Full-Text PDF (323 KB)
   • CrossRef
8. Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971–975
   • View In Article
   • MEDLINE
   • CrossRef
9. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–1010
   • View In Article
   • CrossRef
10. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123–129
    • View In Article
    • Abstract
    • Full Text
    • Full-Text PDF (94 KB)
    • CrossRef
11. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–2695
    • View In Article
    • CrossRef
12. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808–816
    • View In Article
    • CrossRef
13. Carreno V, Castillo I, Molina J, et al. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol. 1992;15:102–106
    • View In Article
    • MEDLINE
    • CrossRef
14. Fattovich G, Giustina G, Realdi G, et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa (European Concerted Action on Viral Hepatitis (EUROHEP)). Hepatology. 1997;26:1338–1342
    • View In Article
    • MEDLINE
    • CrossRef
15. Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med. 1991;114:629–634
    • View In Article
    • MEDLINE
16. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat. 1998;5:389–397
    • View In Article
    • MEDLINE
    • CrossRef
17. Lok AS, Chung HT, Liu VW, et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology. 1993;105:1833–1838
    • View In Article
    • Abstract
    • Full-Text PDF (592 KB)
18. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334:1422–1427
    • View In Article
    • MEDLINE
    • CrossRef
19. van Zonneveld M, Flink HJ, Verhey E, et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther. 2005;21:1163–1171
    • View In Article
    • MEDLINE
    • CrossRef
20. van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut. 2003;52:420–424
    • View In Article
    • MEDLINE
    • CrossRef
21. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001;33:1527–1532
    • View In Article
    • MEDLINE
    • CrossRef
22. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004;19:1276–1282
    • View In Article
    • MEDLINE
    • CrossRef
23. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006;44:1656–1665
    • View In Article
    • MEDLINE
    • CrossRef
24. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743–1751
    • View In Article
    • Abstract
    • Full Text
    • Full-Text PDF (289 KB)
    • CrossRef
25. Cooksley G, Lau GKK, Liaw YF, et al. Effects of genotype and other baseline factors on response to peginterferon alfa-2a (40 kDa) (Pegasys®) in HBeAg-positive chronic hepatitis B: results from a large, randomised study. J Hepatol. 2005;42:S30
    • View In Article
26. Bonino F, Lau GKK, Marcellin P, et al. The first detailed analysis of predictors of response in HBeAg-negative chronic hepatitis B: data from a multicenter, randomized, partially double-blind study of peginterferon-alfa-2a (4-KD) (Pegasys®) alone or in combination with lamivudine vs lamivudine alone. Hepatology. 2004;40:A1142
    • View In Article
27. European Association for the study of the liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–242
    • View In Article
    • Full Text
    • Full-Text PDF (244 KB)
    • CrossRef
28. Pas SD, Fries E, De Man RA, et al. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol. 2000;38:2897–2901
    • View In Article
    • MEDLINE
29. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York, NY: Springer–Verlag; 2001;
    • View In Article
30. Steyerberg EW, Eijkemans MJ, Harrell FE, et al. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med. 2000;19:1059–1079
    • View In Article
    • MEDLINE
    • CrossRef
31. Steyerberg EW, Harrell FE, Borsboom GJ, et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54:774–781
    • View In Article
    • Abstract
    • Full Text
    • Full-Text PDF (97 KB)
    • CrossRef
32. Harrell FE. Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. New York: Springer-Verlag, LLC; 2006;
    • View In Article
33. de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002, Geneva, Switzerland. Consensus statement (long version) J Hepatol. 2003;39:S3–S25
    • View In Article
34. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263–283
    • View In Article
35. Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003;38:1267–1273
    • View In Article
    • MEDLINE
    • CrossRef
36. Ryu SH, Chung YH, Choi MH, et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol. 2003;39:614–619
    • View In Article
    • Abstract
    • Full Text
    • Full-Text PDF (114 KB)
    • CrossRef
37. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–2588
    • View In Article
    • CrossRef
38. Poynard T, Hou JL, Chutaputti A, et al. Sustained durability of HBeAg seroconversion in chronic hepatitis B patients after treatment with telbivudine. J Hepatol. 2008;48:S263–S264
    • View In Article
    • Full-Text PDF (55 KB)
    • CrossRef
39. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol. 2008;48(Suppl 1):S2–S19
    • View In Article
    • Abstract
    • Full Text
    • Full-Text PDF (251 KB)
    • CrossRef
40. Craxi A, Di Bona D, Camma C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol. 2003;39(Suppl 1):S99–S105
    • View In Article
41. Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology. 2008;47:428–434
    • View In Article
    • CrossRef
42. Buster EH, Hansen BE, Zeuzem S, et al. Predicting sustained HBeAg loss after treatment with peginterferon alpha-2b: development and validation of a practical model. Hepatology. 2007;46:684A–685A
    • View In Article
43. Grandjacques C, Pradat P, Stuyver L, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol. 2000;33:430–439
    • View In Article
    • Abstract
    • Full Text
    • Full-Text PDF (1290 KB)
    • CrossRef
44. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46:45–52
    • View In Article
    • Abstract
    • Full Text
    • Full-Text PDF (231 KB)
    • CrossRef
45. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73
    • View In Article
    • CrossRef
46. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686
    • View In Article
    • Abstract
    • Full Text
    • Full-Text PDF (180 KB)
    • CrossRef
47. Marcellin P, Piratvisuth T, Brunetto MR, et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40kD) with or without lamivudine: results of 4-year follow-up. J Hepatol. 2008;48:S46
    • View In Article
    • Full-Text PDF (62 KB)
    • CrossRef